Therapeutic concentrations of valproate but not amitriptyline increase neuropeptide Y (NPY) expression in the human SH-SY5Y neuroblastoma cell line

Article ID	Journal	Published Year	Pages	File Type
8361033	Regulatory Peptides	2013	8 Pages	PDF

Abstract

Together, the data point to an elevation of human NPY mRNA and peptide levels by therapeutic concentrations of VPA following chronic treatment. Thus, upregulation of NPY may have an impact in anti-cancer treatment of neuroblastomas with VPA, and antagonizing hypothalamic NPY effects may help to ameliorate VPA-induced weight gain and obesity without interfering with the desired central effects of VPA.

Keywords

CREB Ngn1 Protein L-isoaspartyl methyltransferase ATOH1 polypeptide YY VPA sdhA PYY NADPHd PKC GSK3 AP-1 FCS HBSS NPY 12-O-tetradecanoylphorbol-13-acetate NOS qRT-PCR HDAC ERK tPA PBS PI3K 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide AmI BDNF Hanks balanced salt solution MAPK MTT PIMT Amitriptyline Depression Epilepsy Trk base pair NADPH diaphorase reverse transcription Cancer fetal calf serum Brain-derived neurotrophic factor Phosphate buffered saline phosphatidylinositide 3-kinase Bone metabolism Obesity Selective serotonin reuptake inhibitor SSRI crossing point noradrenalin nitric oxide synthase histone deacetylase Sodium valproate quantitative reverse transcription polymerase chain reaction Pancreatic polypeptide activator protein 1 cAMP response element-binding protein Protein kinase C mitogen-activated protein kinase extracellular signal-regulated kinase glycogen synthase kinase-3 Neuropeptide Y